Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if the combination of 177Lu-girentuximab and nivolumab is
a safe and effective treatment for advanced clear cell renal cell carcinoma/ccRCC that has
the CAIX protein.